Surgical Science shares fell 9.46% in premarket trading to $56.45, down from a previous close of $62.35, after the company reported its third-quarter 2026 results. The company said sales were SEK 260 million, down 1% year over year, against a strong comparison quarter that benefited from delayed orders.
Adjusted EBIT margin reached 15%, in line with the company's financial target. Gross margin rose 3 percentage points to 68%. License revenue grew 16% to SEK 76 million, and service revenue rose 15%. Simulator sales fell 7% to SEK 143 million.
For the first nine months of 2026, sales rose 4% in Swedish kronor, or 5% in local currencies, to SEK 750 million. The company said growth remains below its target level.
Sales in the United States rose almost 50% year over year in the quarter, and the Americas region grew 30%. Chief executive Tom Englund said: "Quarter three was another step in the right direction for Surgical Science. If I should summarize the quarter in one sentence, it would be on the right track with profitability, and our strategy is delivering."
Management said it expects to reach its full growth and profitability targets in 2027. The source did not include actual EPS or revenue figures, so a comparison with forecasts cannot be made from the material provided.